经贵要静脉植入式静脉输液港  

Implantable venous access port via basilic vein

作　　者：刘倩[1] 赵璇[1] 辛灵[1] 刘荫华[1] Liu Qian;Zhao Xuan;Xin Ling;Liu Yinhua(Peking University First Hospital,Beijing 100034,China)

机构地区：[1]北京大学第一医院,北京100034

出　　处：《中华普外科手术学杂志（电子版）》2023年第3期255-255,共1页Chinese Journal of Operative Procedures of General Surgery(Electronic Edition)

基　　金：北京健康促进会基金,北京医学奖励基金会青年培育基金(20180502)。

摘　　要：乳腺癌系统治疗在延长患者生存期,降低复发风险的价值已获得临床广泛共识。化疗作为乳腺癌系统治疗重要手段,常常包含发疱类药物、腐蚀性药物。《中华人民共和国卫生行业标准一静脉治疗护理技术规范操作》规定发疱类药物、腐蚀性药物不宜使用外周静脉输注。为规范乳腺癌患者化疗输液通路的临床应用,中华医学会外科学分会乳腺外科学组发布《乳腺癌中心静脉血管通路临床实践指南》,推荐植入式静脉输液港作为乳腺癌患者化疗的安全输液通路。经贵要静脉植入式静脉输液港由于操作安全,气胸、血胸等严重并发症发生率低,可作为乳腺癌化疗植入静脉输液港的可选术式之一。Systematic treatment of breast cancer can reduce the risk of recurrence and prolong the survival,which has been widely recognized in clinical practice.Chemotherapy for breast cancer patients often contains corrosive drugs.According to the Health Industry Standard of China,corrosive drugs should not be infused through peripheral vein.In order to standardize the clinical application of chemotherapy infusion pathway,the Chinese Society of Breast Surgery(CSBrS)issued the Clinical Practice Guide for Central Venous Access for breast cancer,and recommended totally implantable venous access port as a safe infusion access for chemotherapy.Due to the safe operation precedure and low incidence of serious complications such as pneumothorax and hemothorax,implantable venous access port via basilic vein can be used as one of the options for chemotherapy infusion pathway.

关 键 词：乳腺肿瘤 贵要静脉 青静脉输液港 

分 类 号：R737.9[医药卫生—肿瘤]